Skip to content

Lycopene nephrotoxicity prevention in cancer patients

Preventive effect of lycopene on cisplatin nephrotoxicity in cancer patient

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016050427745N1
Enrollment
120
Registered
2016-07-31
Start date
2015-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug induced nephropathy. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Lycopene 25mg tablet bid 24hr before until 72hr left after cisplatin injection and an standard regimen of kidney injury prevention (hydration+sulphate magnesium). Intervention 2: Cispl
Treatment - Drugs
Lycopene 25mg tablet bid 24hr before until 72hr left after cisplatin injection and an standard regimen of kidney injury prevention (hydration+sulphate magnesium).
Cisplatin and an standard regimen of kidney injury prevention (hydration+sulphate magnesium).

Sponsors

Vice chancellor for research, Shahrekord university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were condidered to be suffering cancer without primary involvement or renal metastasis; being candidate for administration of 70-100 mg/m2 cisplatin; being 20-80 years old; Cr < 1.5; normal hearing; no underlying nephropathy; ; performance status of 0-2. Exclusion criteria were death; allergy to lycopene; hearing loss; moderate to severe neuropathy; renal metastatic involvement.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
BUN. Timepoint: Before intervention, 7 & 21 days lft. Method of measurement: mg/dl - labratuary.;Cr. Timepoint: Before intervention, 7 & 21 days lft. Method of measurement: mg/dl - labratuary.;GFR. Timepoint: Before intervention, 7 & 21 days lft. Method of measurement: ml/min - calculation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKeivan Mohammadi

Shahrekord university of medical sciences

k1mohamadi@yahoo.com+98 31 3624 7985

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026